Blood draw, Urine draw

PreclinicalBiologic

UUniversity Hospital, Strasbourg, France

Blood draw, Urine draw is one of 31 biologic programs targeting Kidney Transplant. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

Kidney TransplantPreclinical

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Preclinical

16 2

Medrol

Pfizer

Preclinical

12 3

Zemplar

AbbVie

Preclinical

2 4

Sensipar

Amgen

Preclinical

1 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Radicava

Shionogi

Preclinical

1 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

4 9

Jardiance

Boehringer Ingelheim

Preclinical

3 10

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2033

Not yet recruiting

Kidney Transplant

NCT05890430

Clinical

Trials by Indication[1]

Kidney Transplant1 trial

Study of Alloimmune Response in Humoral Rejection After Kidney Transplantation

Not yet recruiting·UUniversity Hospital, Strasbourg, France··NCT05890430·570 enrolled

Infants1 trial

Apparent Life Threatening Events, Sudden Infant Death Syndrome and Muscarinic Receptors

Terminated·UUniversity Hospital, Strasbourg, France·Preclinical·NCT03278977·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Blood draw, Urine draw. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blood draw, Urine draw compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blood draw, Urine draw. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Strasbourg, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Strasbourg, France

Blood draw, Urine draw

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2033

Trials by Indication[1]

Kidney Transplant1 trial

Infants1 trial

References

Drug Info

Quick Facts

Related News